Saturday, December 3, 2022

561.316.3330

Biotechnology News Magazine

GTCR and Carlyle-Backed Resonetics Announces Acquisition of Agile MV

Latest Posts

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Venetoclax is a BCL-2 inhibitor approved by the U.S. Food and Drug Administration (FDA) for treatment of several hematologic cancers, including in combination with azacytidine for elderly patients with AML unable to tolerate the standard of care.

Acer Therapeutics Announces $1.5M Private Placement

The proceeds from the private placement will be used by Acer Therapeutics for working capital and general corporate purposes and, together with Acer’s existing cash and cash equivalents, are expected to be sufficient to fund the Company’s anticipated operating and capital requirements through the fourth quarter of 2022.

AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “The selection of ACI-35.030 for further development is a significant step for this collaboration. Early clinical testing showed that ACI-35.030 was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and enriched paired helical filaments (ePHF) species, both of which are closely implicated in Alzheimer’s disease (AD).

TransCode Therapeutics Announces eIND Submission to US FDA for Planned First-in-Human Clinical Trial in Patients with Advanced Solid Tumors

The planned clinical trial is to evaluate TransCode’s lead therapeutic candidate, TTX-MC138, in cancer patients with advanced solid tumors. ​TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode Therapeutics believes that TTX-MC138 could be used as a treatment for many of these cancers.

GTCR, a leading private equity firm, announced that its portfolio company Resonetics, a pioneer in advanced engineering and manufacturing solutions for the life sciences industry, has acquired Agile MV (“Agile”).

Based in Montreal and founded in 2010, Agile MV is an emerging leader in product development and turnkey device assembly serving the high-growth electrophysiology and interventional cardiology catheter market.

Agile’s expertise in state-of-the-art, minimally invasive and interventional medical devices complements Resonetics’ existing product development capabilities in catheter-based delivery systems and implants. Agile represents the tenth add-on acquisition for Resonetics since GTCR invested in the company in February 2018, and the second since Carlyle’s strategic investment in Resonetics in December 2021.

The acquisition furthers the company’s strategy to build a leader in micro-manufacturing for medical devices, targeting fast-growing interventional and minimally invasive applications across the MedTech industry.

Tom Burns, CEO of Resonetics, commented, “Consistent with our initial investment thesis for Resonetics, the acquisition of Agile strategically enhances our capabilities, and further establishes the company’s position as a leading service provider to interventional medical device companies.”

Sean Cunningham, Managing Director and Co-Head of Healthcare at GTCR, added, “We have great respect for what the Agile team has built, and we look forward to our partnership with them. This represents Resonetics’ tenth acquisition since our initial investment, and we expect to continue to aggressively pursue tuck-in acquisitions as well as more transformative opportunities.”

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine